Do you want to participate in a clinical study as a healthy control? - Risk or benefit?

Autor:	Giessen H; Department of Internal Medicine, Kantonsspital Aarau, Aarau 5000, Switzerland., Nebiker CA; Department of Surgery, Kantonsspital Aarau, Aarau 5000, Switzerland., Bruehlmeier M; Department of Nuclear Medicine, Kantonsspital Aarau, Aarau 5000, Switzerland., Spreitzer S; Department of Pathology, Kantonsspital Aarau, Aarau 5000, Switzerland., Mueller B; Department of Internal Medicine, Kantonsspital Aarau, Aarau 5000, Switzerland., Schuetz P; Department of Internal Medicine, Kantonsspital Aarau, Aarau 5000, Switzerland. philipp.schuetz@ksa.ch.
Jazyk:	angličtina
Zdroj:	World journal of clinical cases [World J Clin Cases] 2017 Dec 16; Vol. 5 (12), pp. 437-439.
DOI:	10.12998/wjcc.v5.i12.437
Abstrakt:	A healthy woman volunteered to participate as "healthy control" in a study. An increased level of procalcitonin (PCT) was detected and remained elevated on follow-up measurements. As calcitonin levels were elevated as well, thyroid ultrasound was performed which revealed nodes in both thyroid lobes, one of them showing metabolic activity in positron emission tomography-computed tomography scan. To exclude a malignant thyroid cancer despite the negative findings in a fine needle aspiration the patient underwent thyroidectomy and a medullary thyroid carcinoma (MTC) was detected in the right lobe. MTC is a rare endocrine tumor with a poor prognosis once having spread, therefore early detection remains a priority for the outcome. Screening parameter is serum calcitonin, in absence of infection the pro-hormone PCT can be used as a screening parameter as well with high sensitivity. Competing Interests: Conflict-of-interest statement: All contributing authors have no financial and personal relationships with other people or organisations that could inappropriately influence or bias their work.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu